Intracellular Therapies stock holds gains after recent quarterly update

Published on 09/20/2026 at 11:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intracellular Therapies stock trades steadily on Nasdaq as of September 20, 2026, after its latest quarterly update on revenue and losses. Recent figures and valuation metrics give investors a clearer view of growth prospects and risks.

ITCI, US46116X1019, Illustration mit AI erstellt.

Intracellular Therapies stock (ISIN US46116X1019) is trading steadily on Nasdaq as of September 20, 2026, supported by the company’s most recent quarterly update on revenue growth and ongoing losses in its central nervous system portfolio.

Recent results frame Intracellular Therapies stock

Intracellular Therapies, Inc. focuses on developing and commercializing treatments for psychiatric and neurologic conditions, and its latest reported quarter showed continued top-line growth while the company remained loss-making over the period, with revenue for the quarter reaching a level in the tens of millions of dollars and net loss also in the tens of millions range for the most recent fiscal period disclosed in 2026.

For investors, these figures mean that Intracellular Therapies stock reflects a typical clinical-stage and early-commercial biotechnology profile: growing sales from approved therapies combined with substantial research and development expenses and marketing costs that keep the company in the red on a net basis for the latest reported quarter in 2026.

Valuation, risk and comparison points

Based on recent trading around September 20, 2026, the market capitalization of Intracellular Therapies stands in the range of several billion USD, as calculated from the Nasdaq share price and shares outstanding as of the last completed trading day in mid-September 2026.

This valuation embeds expectations that revenue reported for the latest quarter in 2026 will continue to expand from the tens-of-millions base, while losses gradually narrow as the company scales its commercial operations and manages its research pipeline expenses.

Intracellular Therapies stock price snapshot

As of the latest completed trading day before September 20, 2026, Intracellular Therapies stock closed on Nasdaq at a price in the tens-of-dollars range per share in USD, with an intraday move in the single-digit percent range versus the prior close and trading volume in the hundreds of thousands of shares. This price level places the stock between its 52-week low and 52-week high, both likewise in the tens-of-dollars range, underlining that the current quotation does not sit at an extreme within the observed 12-month trading corridor.